FindTrial
Sign In

DOXORUBICINE TEVA 50 mg/25 ml

DRUG3 trials

Sponsors

Asoc Grupo Espanol De Investigacion En Sarcomas, Oncopole Claudius Regaud, Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Conditions

NOS sarcomaPhase I:Adult patients with centrally confirmed diagnosis of advanced/metastatic undifferentiated pleomorphic sarcomaSoft Tissue SarcomaStage IIIbreast cancerepitheloid sarcomafibrosarcomahigh-grade uterine sarcomas (excluding those with BCOR or NTRK translocation). Phase II:Adult patients with centrally confirmed diagnosis of advanced/metastatic undifferentiated pleomorphic sarcoma or leiomyosarcoma.

Phase 1

Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas
CompletedCTIS2024-510877-67-00
Asoc Grupo Espanol De Investigacion En Sarcomasepitheloid sarcoma, fibrosarcoma, high-grade uterine sarcomas (excluding those with BCOR or NTRK translocation). Phase II:Adult patients with centrally confirmed diagnosis of advanced/metastatic undifferentiated pleomorphic sarcoma or leiomyosarcoma. +9
Start: 2024-05-14End: 2025-11-13Target: 157Updated: 2025-10-15

Phase 3

Interest of peri operative CHemotherapy In patients with CINSARC high-risk localized Soft Tissue Sarcoma
RecruitingCTIS2024-515384-62-00
Oncopole Claudius RegaudSoft Tissue Sarcoma
Start: 2020-10-09Target: 600Updated: 2025-12-23
Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial
RecruitingCTIS2024-516196-32-00
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichtingbreast cancer, Stage III
Start: 2017-01-01Target: 172Updated: 2025-01-29